We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
ZeptoMetrix an Antylia scientific company

Download Mobile App




Vaccine Prevents Prion Disease in Laboratory Mice

By Biotechdaily staff writers
Posted on 14 May 2007
An oral vaccine can prevent mice from developing a brain disease similar to mad cow disease, according to investigators. More...


Prion diseases, which include scrapies, mad cow disease, and chronic wasting disease, are fatal and currently there is no treatment or cure. The disease spreads when an animal eats the body parts of other animals contaminated with prions. The disease causes dementia and abnormal limb movements.

Prion is a protein that is also an infectious agent. The proteins are so similar to proteins found normally so that the immune system does not fight them off. To devise a vaccine that would stimulate the mice's immune system, researchers attached prion proteins to a genetically engineered strain of Salmonella.

For the study, the mice were orally vaccinated with a safe, attenuated Salmonella strain, which expressed the prion protein. The mice were then divided into two groups--those who had high levels of antibodies in their blood and therefore responded well to the vaccine, and those with low levels of antibodies.

The mice with high levels of antibodies had no symptoms of the disease after 400 days. The mice with low levels of antibodies also had a considerable delay in the onset of the disease. It typically takes 120 days for mice that have not been vaccinated to develop the disease.

"These are promising findings,” said study author Thomas Wisniewski, M.D., from the New York University (NYU) School of Medicine (New York, NY, USA) and a member of the American Academy of Neurology. "We are now in the process of redesigning the vaccine so it can be used on deer and cattle.”

Dr. Wisniewski reported that much more research is still needed before the vaccine could be considered for humans. "The human version of prion disease usually occurs spontaneously and only rarely because of eating contaminated meat. But if, for example, a more significant outbreak of chronic wasting disease in deer and elk occurs and if it were transmissible to humans, then we would need a vaccine like this to protect people in hunting areas.”

Dr. Wisniewski also noted that a vaccine that decreases the spread of prion disease in animals also decreases the possibility that the disease could infect humans. These findings were presented at the American Academy of Neurology's 59th annual meeting in Boston, MA, USA, April 28-May 5, 2007.


Related Links:
New York University School of Medicine

Platinum Member
Xylazine Immunoassay Test
Xylazine ELISA
Verification Panels for Assay Development & QC
Seroconversion Panels
Complement 3 (C3) Test
GPP-100 C3 Kit
Gold Member
Pipette Controller
Sapphire MaxiPette
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.